RT Book, Section
A1 McQuaid, Kenneth R.
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1193150753
T1 Diarrhea
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193150753
RD 2024/04/19
AB Key  Clinical  Updates  in  DiarrheaImmune  checkpoint  inhibitor  therapy  for  malignancies  may  cause  mild  to  severe  GI  side  effects  in  8–27%  of  patients.Patients  with  severe  diarrhea  or  dysentery  and  a  known  history  of  IBD  or  prior  immune  checkpoint  inhibitor  therapy  require  expedited  evaluation  with  stool  studies  and  possible  sigmoidoscopy  or  colonoscopy  with  biopsy  to  exclude  infection  prior  to  therapy  with  intravenous  corticosteroids.Shiga-toxin–producing  Escherichia  coli  infection  should  not  be  treated  with  antibiotics  due  to  an  increased  risk  of  hemolytic-uremic  syndrome,  especially  in  children.Dougan  M  et  al.  Gastroenterology.  [PMID:  33080231]Siciliano  V  et  al.  Rev  Recent  Clin  Trials.  [PMID:  32598272]Elevated  fasting  levels  (>  48  ng/mL)  of  the  bile  acid  precursor  7aC4  are  strongly  predictive  of  bile  acid  diarrhea.Borup  C  et  al.  Am  J  Gastroenterol.  [PMID:  32740083]